• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Know Labs Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Unregistered Sales of Equity Securities, Material Modification to Rights of Security Holders, Financial Statements and Exhibits

    6/4/25 5:07:06 PM ET
    $KNW
    Industrial Machinery/Components
    Industrials
    Get the next $KNW alert in real time by email
    knwn_8k.htm
    0001074828false--09-3000010748282025-05-302025-05-30iso4217:USDxbrli:sharesiso4217:USDxbrli:shares

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

    CURRENT REPORT

     

    Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): May 30, 2025

    knwn_8kimg1.jpg 

    KNOW LABS, INC.

    (Exact name of registrant as specified in its charter)

     

    Nevada

     

    001-37479

     

    90-0273142

    (State or other jurisdiction

    of incorporation)

     

    (Commission

    File Number)

     

    (IRS Employer

    Identification No.)

     

    619 Western Avenue, Suite 610, Seattle, Washington 

     

    98104

    (Address of principal executive offices)

     

    (Zip Code)

     

    (206) 903-1351

    (Registrant's telephone number, including area code)

     

     ______________________________________

    (Former name or former address, if changed since last report.)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading Symbol(s)

     

    Name of each exchange on which registered

    Common Stock, par value $0.001

     

    KNW

     

    NYSE American LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

     

    Emerging Growth Company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

    Item 1.01

    Entry into a Material Definitive Agreement

     

    On June 2, 2025, Know Labs, Inc., a Nevada corporation (the “Company”) entered into a Promissory Note Conversion Agreement (the “Conversion Agreement”) with J3E2A2Z LP (“J3E2A2Z”), an entity affiliated with and controlled by Ronald P. Erickson, the Company’s Chief Executive Officer, and the holder of two convertible redeemable promissory notes, pursuant to which J3E2A2Z agreed to exchange approximately $1.18 million in aggregate  principal owed under the J3E2A2Z Converted Notes (defined below) for shares of the Company’s newly designed class of convertible preferred stock, discussed herein.

     

    On May 30, 2025, the Company’s Board of Directors, upon recommendation of the Nominating and Governance Committee of the Board of Directors, approved entry into the Conversion Agreement and authorized from its blank check preferred stock a new “Series H Convertible Preferred Stock”. The terms of the Series H Convertible Preferred Stock is discussed in greater detail in Item 5.03 of this Current Report on Form 8-K.Pursuant to the Conversion Agreement with J3E2A2Z the Company converted $1,184,066 in aggregate principal (“J3E2A2Z Debt Amount”) owed to J3E2A2Z pursuant to the two outstanding Convertible Redeemable Promissory Notes, each dated January 31, 2018 (collectively, the “J3E2A2Z Converted Notes”),  into an aggregate 16,916 shares of Series H Convertible Preferred Stock.  Upon the consummation of the Conversion Agreement with J3E2A2Z, the J3E2A2Z Debt Amount will no longer be outstanding, however any accrued and unpaid interest shall remain outstanding due and payable under the J3E2A2Z Converted Notes.

     

    J3E2A2Z received one share of Series H Convertible Preferred Stock for every $70.00 in principal converted under the Conversion Agreement. The Series H Convertible Preferred Stock is convertible into Company common stock at an initial conversion price of $0.335 per share (“Conversion Price”), subject to potential future adjustment. The holder of Series H Convertible Preferred Stock is entitled to cast the number of votes equal to the number of shares of Company common stock into which the Series H Convertible Preferred Stock held by such holder are convertible, subject to a beneficial ownership limitation of 19.99%, unless stockholder approval is obtained. Each outstanding share of Series H Convertible Preferred Stock accrues cumulative dividends at a rate equal to 8.0% per annum of the stated value (currently $70.00, subject to adjustment as provided in the certificate of designation). The foregoing description of the Series H Convertible Preferred Stock is not complete and is qualified in its entirety by reference to the full text of the certificate of designation, a copy of which is filed as Exhibit 3.1 and as further discussed in Item 5.03 of this Form 8-K.

     

    The issuance of the Series H Convertible Preferred Stock was made in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act.

     

    The form of Conversion Agreement and certificate of designation of Series H Convertible Preferred Stock are attached as exhibits to this Current Report on Form 8-K to provide security holders with information regarding their terms. Except for their status as contractual documents that establish and govern the legal relations between the parties with respect to the transaction described above, the documents are not intended to be a source of factual, business or operational information about the parties. Representations and warranties may be used as a tool to allocate risks between the parties to each Agreement, including where the parties do not have complete knowledge of all facts, instead of establishing these matters as facts. Furthermore, they may be subject to standards of materiality applicable to the contracting parties, which may differ from those applicable to investors. Accordingly, investors and security holders should not rely on such representations and warranties as characterizations of the actual state of facts or circumstances, because they were only made as of the date of each Conversion Agreement. Moreover, information concerning the subject matter of such representations and warranties may change after the date of each Conversion Agreement, which subsequent information may or may not be fully reflected in the Company’s public disclosures.

     

    The foregoing description of the certificate of designation for the Series H Convertible Preferred Stock and Conversion Agreement is not complete and each is qualified in its entirety by reference to the full text of the documents, copies of which are filed as Exhibit 3.1 and 10.1, respectively, to this Current Report on Form 8-K and are incorporated by reference herein.

     

    Item 3.02

    Unregistered Sales of Equity Securities 

     

    The information contained in Item 1.01 is incorporated herein by reference. 

     

    As described in Item 1.01, under the terms of the Conversion Agreement, the Company has agreed to issue shares of Series H Convertible Preferred Stock as part of a debt conversion to J3E2A2Z, an entity affiliated with Ronald Erickson, the Company’s CEO. This issuance and sale will be exempt from registration under the Securities Act of 1933, as amended (the “Securities Act”), pursuant to Section 4(a)(2) of the Securities Act. The stockholder receiving the Series H Convertible Preferred Stock has represented that it is an “accredited investor” as defined in Rule 501 under the Securities Act and that the shares are being acquired for investment purposes and not with a view to or for sale in connection with any distribution thereof, and appropriate legends will be affixed to the securities.

     

    Item 3.03

    Material Modification to Rights of Security Holders

     

    The description of the Series H Convertible Preferred Stock described in Item 1.01 and Item 5.03 are incorporated herein.

     

     
    2

     

     

    Item 5.03

    Amendments to Articles of Incorporation of Bylaws; Change in Fiscal Year 

     

    Pursuant to the Company’s articles of incorporation, the Company is authorized to issue 5,000,000 shares of blank check preferred stock of which 30,000 shares have been designated as our Series C Convertible Preferred Stock and 20,000 shares have been designated as our Series D Convertible Preferred Stock. 

     

    On May 30, 2025, in connection with the Conversion Agreement, the Company’s Board of Directors approved the adoption and filing of a Certificate of Designation for 30,000 shares of Series H Convertible Preferred Stock (“Series H Certificate of Designation”), a newly created classes of preferred stock. The Series H Certificate of Designation were filed and became effective with the Secretary of State of Nevada on June 2, 2025. 

     

    Series H Convertible Preferred Stock

     

    Of our authorized preferred stock, 30,000 shares have been designated as Series H Convertible Preferred Stock, or the Series H Preferred Stock. 

     

    With respect to dividend rights and rights on liquidation, winding up and dissolution, shares of our Series H Preferred stock ranks junior to the Corporation’s Series C Convertible Preferred Stock and Series D Convertible Preferred Stock,  and ranks senior to our common stock and any series of Preferred Stock created hereafter. Holders of Series H Preferred Stock have no preemptive or subscription rights and there are no sinking fund provisions applicable to the Series H Preferred Stock. The rights, preferences and privileges of the holders of Series H Preferred Stock are subject to, and may be adversely affected by, the rights of the holders of shares of any other series of preferred stock.

     

    In addition to any class voting rights provided by the Nevada Revised Statutes or the certificate of designation for the Series H Preferred Stock, holders of Series H Preferred Stock have the right to vote, on an as-if-converted-to-common-stock basis (but subject to, and after giving effect to, the conversion limitations described below, applied effective as of the record date for determining the stockholders entitled to vote). Further, as long as any shares of Series H Preferred are outstanding, the Company shall not, among other things, without the affirmative vote of the holders of at least a majority on voting power of the outstanding shares of Series H Preferred Stock: (a) alter or change adversely the powers, preferences or rights given to the Series H Preferred Stock or alter or amend the Series H Preferred Stock certificate of designation, (b) issue any other class or series of capital stock ranking senior to or on parity the Series H Preferred Stock as to dividends or up liquidation or reclassify any shares of common stock or any series of capital stock into shares having preference or priority as to dividends or upon liquidation superior to or on parity with any such preference or priority of Series H Preferred Stock, or (c) enter into any agreement with respect to any of the foregoing.

     

    Each outstanding share of Series H Preferred Stock accrues cumulative dividends at a rate equal to 8.0% per annum of the Series H Preferred Stock stated value (currently $70.00, subject to adjustment as provided in the Series H Preferred Stock certificate of designation).  Dividends, whether accrued, declared or payable are payable, at the election of the Holder, either (i) via wire transfer or other payment of immediately available funds, or (ii) in the form of additional shares of Series H Preferred Stock.  Such dividends are payable only upon conversion of the shares of Series H Preferred Stock, or when, as and if otherwise declared by our board of directors.

     

    Each holder of any shares of Series H Preferred Stock has the right, at its option at any time following September 30, 2025 (the “Redemption Date”), to convert such holder’s shares of Series H Preferred Stock into shares of our common stock in accordance with the terms of the Series H Preferred Stock certificate of designation.  However, unless the Corporation obtains the approval of its stockholders for issuances of Common Stock in excess of such amount, we shall not effect a conversion of the Series H Preferred Stock, and the holder of any shares of Series H Preferred Stock shall not have the right to voluntarily convert such holder’s shares of Series H Preferred Stock, to the extent that after giving effect to such exercise, such holder (together with such holder’s affiliates) would beneficially own in excess of 19.99% of the shares of our common stock outstanding immediately after giving effect to such conversion. 

     

    At any time after the Redemption Date, the holder of Series H Preferred Stock shall have the right to elect to have, out of funds legally available therefor, all or any portion of the then outstanding shares of Series H Preferred Stock or accrued and unpaid PIK Dividends (as defined in the certificate of designation) immediately redeemed by the Corporation for a price per share equal to the stated value, all as set forth in the Series H Preferred Stock certificate of designation.  Further, if at any time after the date of issuance of the Series H Preferred Stock there shall have been a Change in Control (as defined in the certificate of designation), upon receipt of a Change in Control Notice, the holder shall have the right to elect to have, out of funds legally available therefor, all (but not less than all) of the then outstanding shares of Series H Preferred Stock immediately redeemed by the Corporation for a price per share equal the stated value, payable in cash or common stock at holder’s election.

     

    The Series H Preferred Stock also has price-based, “full-ratchet,” and proportional anti-dilution rights, based on issuance or deemed issuances of our securities below the current conversion price of $0.50 per share, all as set forth in the Series H Preferred Stock certificate of designation. 

     

    The foregoing description of the Series H Preferred Stock Certificate of Designation does not purport to be complete and is qualified in its entirety by reference to the complete text of the Series H Preferred Stock Certificate of Designation, which is attached hereto as Exhibit 3.1 and incorporated herein by reference.

     

    Item 9.01

    Financial Statements and Exhibits 

     

    (d) Exhibits 

     

    The following exhibits are filed herewith: 

     

    Exhibit No.

     

    Description

    3.1

     

    Certificate of Designation of the Series H Convertible Preferred Stock of Know Labs, Inc.

    10.1

     

    Promissory Note Conversion Agreement between Know Labs, Inc. and J3E2A2Z LP, dated June 2, 2025

     

     
    3

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

     

    KNOW LABS, INC.

     

     

     

     

     

    Date: June 4, 2025

    By: 

    /s/ Ronald P. Erickson

     

     

    Name: 

    Ronald P. Erickson

     

     

    Title:

    Chief Executive Officer 

     

     

     
    4

     

    Get the next $KNW alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $KNW

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $KNW
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Know Labs Inc. (Amendment)

      SC 13D/A - KNOW LABS, INC. (0001074828) (Subject)

      6/3/24 2:11:39 PM ET
      $KNW
      Industrial Machinery/Components
      Industrials
    • SEC Form SC 13D filed by Know Labs Inc.

      SC 13D - KNOW LABS, INC. (0001074828) (Subject)

      10/25/23 7:27:11 PM ET
      $KNW
      Industrial Machinery/Components
      Industrials
    • SEC Form SC 13D/A filed by Know Labs Inc. (Amendment)

      SC 13D/A - KNOW LABS, INC. (0001074828) (Subject)

      10/19/23 6:32:18 AM ET
      $KNW
      Industrial Machinery/Components
      Industrials

    $KNW
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Greg Kidd to Acquire Controlling Interest in Know Labs and Introduce Bitcoin Treasury Strategy

      Know Labs, Inc. (NYSE American: KNW ("Know Labs" or the "Company"), a technology innovator specializing in non-invasive health monitoring solutions, today announced that it has entered into an agreement with Goldeneye 1995 LLC ("Buyer"), an affiliate of fintech investor, entrepreneur, and former Ripple Chief Risk Officer, Greg Kidd, to acquire a controlling interest in the Company. Upon the closing of the transaction, Mr. Kidd will become Chief Executive Officer and Chairman of the Board of Directors of the Company. Under the terms of the agreement, the Buyer will acquire that number of shares of the Company's common stock obtained by dividing (i) the sum of 1,000 Bitcoin and a cash sum t

      6/6/25 9:00:00 AM ET
      $KNW
      Industrial Machinery/Components
      Industrials
    • Know Labs Sensor Non-Invasively Identifies pH Levels in Real Time

      Significant Applications in Health Care, Food Quality and Safety and More Know Labs, Inc. (NYSE:KNW) is pleased to announce that it has completed extensive research in its laboratory utilizing its patented Radio Frequency Dielectric Spectroscopy (RFDS) sensor technology to identify changes in pH levels in real time. The research has been submitted for peer reviewed publication. The research is available for review today here on the Company's website at www.knowlabs.co. An abstract of the paper states, "We describe an experiment in which we employ a radio frequency sensor to measure pH changes in a liquid solution. The experiment is novel in a few ways. First, the sensor does not have cont

      3/19/25 9:00:00 AM ET
      $KNW
      Industrial Machinery/Components
      Industrials
    • Know Labs to Attend the 18th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD)

      The company to meet with potential strategic partners to discuss collaborating on advancing clinical research of its non-invasive blood glucose monitor Know Labs, Inc. (NYSE:KNW), an emerging developer of non-invasive medical diagnostic technology with its Radio Frequency Dialectic Spectroscopy (RFDS) platform, today announced the company will be attending The 18th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) Technology Fair in Amsterdam, Netherlands on March 19-22, 2025. The Company will share updates on the development of its non-invasive blood glucose monitor, since last year's conference, and discuss opportunities for collaboration and partnership

      3/18/25 9:00:00 AM ET
      $KNW
      Industrial Machinery/Components
      Industrials

    $KNW
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by CEO Erickson Ronald P

      4 - KNOW LABS, INC. (0001074828) (Issuer)

      6/4/25 4:15:21 PM ET
      $KNW
      Industrial Machinery/Components
      Industrials
    • Director Takesako Ichiro John Paul was granted 25,000 shares, increasing direct ownership by 645% to 28,875 units (SEC Form 4)

      4 - KNOW LABS, INC. (0001074828) (Issuer)

      5/7/25 4:16:32 PM ET
      $KNW
      Industrial Machinery/Components
      Industrials
    • Director Ellingson Larry K was granted 25,000 shares, increasing direct ownership by 6,188% to 25,404 units (SEC Form 4)

      4 - KNOW LABS, INC. (0001074828) (Issuer)

      5/7/25 4:16:34 PM ET
      $KNW
      Industrial Machinery/Components
      Industrials

    $KNW
    Leadership Updates

    Live Leadership Updates

    See more

    $KNW
    SEC Filings

    See more
    • Know Labs Appoints Chris Somogyi as President, International

      Somogyi to lead Know Labs' "Skunkworks" Program and drive global revenues. Know Labs, Inc. (NYSE:KNW), an emerging leader in non-invasive medical diagnostic technology, today announced the appointment of Chris Somogyi as President, International. With over 40 years of experience in commercializing innovation across related industries, Somogyi brings a wealth of expertise to lead the Company's "Skunkworks" Program and global patent licensing efforts. In his role, Somogyi will focus on identifying new applications of Know Labs' extensive intellectual property (IP) portfolio consisting of over 300 patents issued, pending and in-process and covering more than 100 medical and non-medical app

      5/16/24 9:00:00 AM ET
      $KNW
      Industrial Machinery/Components
      Industrials
    • Know Labs Expands Medical and Scientific Advisory Board

      New Members Bring Extensive Clinical Diabetes Management and FDA Expertise Know Labs, Inc. (NYSE:KNW), an emerging developer of non-invasive medical diagnostic technology, today announced the appointment of four new members to the Company's Medical and Scientific Advisory Board. The new additions to the Advisory Board are Jeff Hitchcock, Karmeen Kulkarni, Dr. Meng Tan and Dr. Satish Garg. They bring to the board extensive experience in clinical diabetes management, including the advancement of new technologies and innovation in medical diagnostics. The Medical and Scientific Advisory Board is chaired by Know Labs' Chief Medical Officer, Dr. James H. "Andy" Anderson. The Advisory Board p

      12/14/23 9:00:00 AM ET
      $KNW
      Industrial Machinery/Components
      Industrials
    • Know Labs Expands Board of Directors

      Appoints Three New Directors with Deep Sector Expertise Know Labs, Inc. (NYSE:KNW), an emerging developer of non-invasive medical diagnostic technology, today announced the appointment of three new members to the Company's Board of Directors. These appointments increase the number of Directors to seven. Each new Director brings to the board extensive sector-relevant experience with deep knowledge of the science and the marketplace that is the focus of Know Labs. The new appointees are John Cronin, Larry Ellingson and Tim Londergan. John Cronin is the founder and CEO of ipCapital Group, Inc., a leading global advisory company on intellectual property strategy and monetization. Cronin beg

      11/8/23 9:00:00 AM ET
      $KNW
      Industrial Machinery/Components
      Industrials
    • Know Labs Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - KNOW LABS, INC. (0001074828) (Filer)

      6/6/25 9:00:35 AM ET
      $KNW
      Industrial Machinery/Components
      Industrials
    • Know Labs Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Unregistered Sales of Equity Securities, Material Modification to Rights of Security Holders, Financial Statements and Exhibits

      8-K - KNOW LABS, INC. (0001074828) (Filer)

      6/4/25 5:07:06 PM ET
      $KNW
      Industrial Machinery/Components
      Industrials
    • SEC Form 10-Q filed by Know Labs Inc.

      10-Q - KNOW LABS, INC. (0001074828) (Filer)

      5/14/25 4:24:08 PM ET
      $KNW
      Industrial Machinery/Components
      Industrials

    $KNW
    Financials

    Live finance-specific insights

    See more
    • Know Labs, Inc. Reports Third Quarter FY2023 Results

      Know Labs, Inc. (NYSE:KNW), an emerging developer of non-invasive medical diagnostic technology, today reported financial results for the third quarter ended June 30, 2023. Financial Highlights: Know Labs reported a net loss of $3.59 million dollars in the third quarter of 2023, compared to a net loss of $3.03 million dollars in the year-ago period, which translates to Earnings Per Share of a loss of $0.07, unchanged from the year ago period of a loss of $0.07 before preferred stock dividends. Recorded a non-cash charge to earnings of $4.96 million related to the fair market value of dividends on the Company's Series C and D preferred stock, that were either paid or accrued in share

      8/14/23 4:15:00 PM ET
      $KNW
      Industrial Machinery/Components
      Industrials
    • Know Labs, Inc. Reports Second Quarter FY2023 Results

      Know Labs, Inc. (NYSE:KNW), an emerging developer of non-invasive medical diagnostic technology, today reported financial results for the second quarter ended March 31, 2023. Financial Highlights: Know Labs reported a net loss of $4.93 million dollars in the second quarter of 2023, compared to a net loss of $6.14 million dollars in the year-ago period, which translates to Earnings Per Share of a loss of $0.10, an improvement over the year ago period of a loss of $0.16. Research and development expense for the second quarter was $2.56 million dollars as compared to $1.25 million dollars in 2022. The increase in R&D expense was related to staff increases in engineering, third party te

      5/15/23 4:05:00 PM ET
      $KNW
      Industrial Machinery/Components
      Industrials
    • Know Labs, Inc. Reports First Quarter 2023 Results

      Know Labs, Inc. (NYSE:KNW), an emerging developer of non-invasive medical diagnostic technology, today reported financial results for the first quarter ended December 31, 2022. Financial Highlights: Know Labs reported a net loss of $3.82 million in the first quarter of 2023, compared to a net loss of $5.36 million in the first quarter of 2022, which translates to Earnings Per Share of a loss of $0.08 versus a loss of $0.15 in the year ago period. Research and development expense for the first quarter ended December 31, 2022, was $1.74 million as compared to $886,000 in the same year ago period. The increase in R&D expense was related to staff increases in engineering, third party techn

      2/14/23 4:00:00 PM ET
      $KNW
      Industrial Machinery/Components
      Industrials